Dealbreaker on MSN17h
AstraZeneca Secures China Rights to Anemia Drug, Buying FibroGen Unit in $160M Deal
By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially ...
FibroGen (NASDAQ:FGEN) vs. Roche (OTCMKTS:RHHBY) Head to Head Survey
FibroGen (NASDAQ:FGEN – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the ...
pharmaphorum23h
AstraZeneca builds in China as Cosette buys Mayne
The week has ended with a flurry of M&A in the drug industry, with Cosette Pharmaceuticals agreeing to buy Australia's Mayne ...
FiercePharma21h
Fierce Pharma Asia—Novo Nordisk's fraud accusation; AstraZeneca's China deal; Ono's FDA nod
Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...
devdiscourse21h
Health Headlines: Global Pharmaceutical Moves and Policy Changes
The health sector is facing significant changes, with the FDA restricting language, New York suing e-cigarette makers, AstraZeneca expanding in China, Eli Lilly stockpiling weight-loss drugs, Teva and ...